Drugs Interfering with Apoptosis in Breast Cancer

Author(s): Daniela Grimm, Markus Wehland, Jessica Pietsch, Manfred Infanger, Johann Bauer

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 3 , 2011

Become EABM
Become Reviewer


Apoptosis plays an important role in development, growth, differentiation, altered gravity conditions, tissue homeostasis, immune defense, and cancer. It can be initiated by external signals via death receptors, but may also emerge from mitochondria. Today most of the key players in cellular apoptosis regulation are identified and can be targeted by therapeutic strategies. In this review we focus on recent development of drugs, which interfere with apoptosis and are currently used or tested for treatment of breast cancer. These novel agents include those targeting the extrinsic pathway such as Fas, tumor necrosis factor – alpha and tumor necrosis factor related apoptosisinducing ligand, as well as drugs targeting the intrinsic Bcl-2 family pathway, or drugs inhibiting repair enzymes such as Poly (ADPribose) polymerase (PARP) inhibitors. Their function will be explained, their role in tumor biology and actual clinical studies will be discussed.

Keywords: Apoptosis, breast cancer, BCL-2, Fas, TNF-alpha, TRAIL, PARP inhibitors

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [272 - 283]
Pages: 12
DOI: 10.2174/138161211795049723
Price: $65

Article Metrics

PDF: 17